Clinical Trials
Dive into the world of clinical trials, where medical innovations are put to the test. Discover ongoing trials, their methodologies, and results. Stay informed about the latest breakthroughs and promising treatments in development. Understand the rigorous process of bringing new therapies to market.
Morphic’s Shares Tumble as Updated Phase 2 Data Casts Shadows on Takeda’s Entyvio Rival
Morphic Therapeutic has encountered a setback, as more comprehensive data from its much-anticipated EMERALD-1 trial unveiled uncertainties, causing its stock ...
Opdivo plus chemo reduces recurrence risk in early-stage lung cancer surgery
In the arena of perioperative treatment for early-stage non-small cell lung cancer (NSCLC) involving PD-1/L1 inhibitors, the competition among key ...
Padcev-Keytruda combo cuts death risk in first-line bladder cancer
As Seagen readies itself for its impending acquisition by Pfizer, a significant triumph emerges for the company’s cancer drug Padcev, ...
Keytruda-Lenvima combo fails to improve survival in two lung cancer trials
Merck and Eisai’s collaborative effort with Keytruda and Lenvima faces yet another setback in their quest to combat cancer. Despite ...
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
Filspari fails to confirm kidney benefit in IgAN, but Travere hopes to keep FDA approval
Half a year after securing accelerated approval for the treatment of a rare kidney ailment, Travere Therapeutics’ groundbreaking drug, Filspari, ...
Relmada reports positive results from open-label trial of REL-1017 for major depressive disorder
Relmada Therapeutics, a central-nervous-system-focused biotech company, has finally glimpsed a ray of optimism after facing setbacks in two phase 3 ...
Scancell’s DNA vaccine shows promising results in phase 2 trial for skin cancer
Scancell’s shareholders are enjoying a prosperous week as the biotech company’s stock surged by 20%, driven by promising preliminary data ...
Arcturus reports positive results for sa-mRNA COVID boosters in phase 1/2 trial
Amid a shrinking COVID-19 vaccine market, Arcturus Therapeutics is forging ahead with its mRNA candidate, revealing promising early data demonstrating ...
Astellas claims positive results for Izervay in geographic atrophy but remains vague on data
Astellas, having recently secured FDA approval for its drug Izervay to treat geographic atrophy (GA), is now in direct competition ...
Guard shares soar as new data show clinical benefit despite missing primary endpoint
Guard Therapeutics is staging a remarkable recovery following a setback in its phase 2 clinical trial for kidney injury treatment. ...
BOTOX Cosmetic shows promise for neck and lower face rejuvenation in phase 3 trial
Allergan Aesthetics, a subsidiary of AbbVie, has unveiled positive top-line findings from the second out of three Phase 3 clinical ...
CEPI funds BioNTech’s mRNA-based mpox vaccine trial with $90 million
BioNTech, the German biotech renowned for its groundbreaking mRNA COVID-19 vaccine, is embarking on clinical trials for an mRNA vaccine ...
Anthos’ ABP-959 outperforms Xarelto in preventing bleeding events in phase 2 trial
Blackstone Life Sciences’ substantial $250 million investment in an ex-Novartis drug candidate has yielded yet another positive outcome in its ...
MDMA shows promise for PTSD treatment in second phase 3 trial, paving way for FDA approval
MAPS Public Benefit Corporation has recently unveiled phase 3 data, marking a significant milestone in its quest for FDA approval ...
Hemogenyx clears FDA hurdle for its novel CAR-T therapy for AML
Hemogenyx Pharmaceuticals has moved a step closer to advancing its CAR-T therapy, HEMO-CAR-T, into clinical trials following the FDA’s acceptance ...
Rocket Pharma gets FDA green light for gene therapy trial, stock surges
Rocket Pharmaceuticals has achieved alignment with the FDA regarding the design of a pivotal phase 2 clinical trial for a ...
Moderna’s mRNA flu vaccine shows phase 3 success, plans for combo shots by 2025
Moderna has achieved significant progress in its quest to develop an mRNA flu vaccine, with the updated mRNA-1010 version successfully ...
Eiger halts hepatitis drug development after liver toxicity, seeks funding for other programs
Eiger BioPharmaceuticals has made the decision to discontinue the pursuit of a home for peginterferon lambda, a drug that was ...
CureVac selects mRNA flu vaccine candidate for GSK collaboration, but data remains secret
CureVac, the renowned biotech company, has made a significant stride in its quest to develop an mRNA influenza vaccine. While ...
Neurocrine advances potential blockbuster drug for endometrial hyperplasia after phase 3 success
Neurocrine Biosciences is banking on its hyperplasia drug, crinecerfont, which analysts predict could be a blockbuster. The company has been ...
Acelyrin’s lead drug flops in phase 3 trial, wiping out half of its market value
Acelyrin, a biotech company based in Los Angeles, has delivered a shocking blow to its investors. Despite successfully raising an ...
Novartis drops Gyroscope’s gene therapy for eye disease after disappointing trial results
Novartis is in the process of divesting its eye disease unit, a move that includes discontinuing a geographic atrophy (GA) ...
ILiAD’s nasal vaccine prevents whooping cough infection in phase 2b trial
ILiAD Biotechnologies, a Florida-based biotech company, is celebrating a significant milestone in the development of its whooping cough vaccine. In ...
J&J’s Rybrevant Beats Chemo In Lung Cancer Patients Who Failed Tagrisso
The medical community buzzed with anticipation when Johnson & Johnson (J&J) released information about Rybrevant, their latest drug venture into ...
Vaxart’s Oral Norovirus Vaccine Misses Primary Endpoint But Shows Some Efficacy In Phase 2
Vaxart finds itself in a precarious position as it grapples with mixed results for its oral monovalent norovirus vaccine candidate, ...
Pfizer’s Lyme Vaccine Shows Strong Booster And Pediatric Effects In Phase 2
Pfizer and Valneva are making strides in their Lyme disease vaccine program, achieving a significant milestone by demonstrating the safety ...
Roche’s $310 Million Gamble On Alnylam Pays Off As Hypertension Drug Shows Promise In Phase 2
Roche’s recent investment of $310 million into metabolic therapy is yielding positive results, as its collaboration with Alnylam in the ...
Janssen Drops Cidara’s Flu Medicine After Disappointing Phase 2 Results
Janssen is honoring its 2021 agreement with Cidara Therapeutics regarding the development of CD388, a flu prophylaxis treatment. However, Janssen ...
J&J Gives Up On $230M Blood Pressure Drug After Disappointing Trial Results
Johnson & Johnson (J&J) is stepping back from its $230 million investment in a blood pressure treatment, aprocitentan, and returning ...
